<--- Back to Details
First PageDocument Content
Nitriles / Pyrimidines / Carbamates / Cyclopropanes / Etravirine / Efavirenz / Darunavir / Investigational New Drug / Rilpivirine / Chemistry / Organic chemistry / Non-nucleoside reverse transcriptase inhibitors
Nitriles
Pyrimidines
Carbamates
Cyclopropanes
Etravirine
Efavirenz
Darunavir
Investigational New Drug
Rilpivirine
Chemistry
Organic chemistry
Non-nucleoside reverse transcriptase inhibitors

22187 Etravirine Clinical PREA

Add to Reading List

Source URL: www.fda.gov

Download Document from Source Website

File Size: 944,60 KB

Share Document on Facebook

Similar Documents

Morphochem’s Investigational New Drug (IND) application accepted by FDA – Novel antibacterial for IV treatment of CDI ready to move to Phase 2 Munich (Germany), June 22, 2016 — Morphochem, a clinical-stage pharmace

DocID: 1uvYN - View Document

Guidance for Industry Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic,

DocID: 1sDEk - View Document

Medical research / Health / Food and Drug Administration / Pharmaceutical industry / Drug safety / Clinical pharmacology / Expanded access / Clinical trial / Investigational New Drug / Informed consent / New drug application / Health Insurance Portability and Accountability Act

Emergency Use: means the use of a test article on a human subject in a life-threatening situation in

DocID: 1riMu - View Document

Health / Pharmaceutical industry / Food and Drug Administration / Pharmacology / Pharmaceuticals policy / Food law / Food safety / Good manufacturing practice / Compounding / Title 21 of the Code of Federal Regulations / Federal Food /  Drug /  and Cosmetic Act / Investigational New Drug

Microsoft Word - 7494fnl.doc

DocID: 1qYy2 - View Document

Food and Drug Administration / Health / Medical research / Pharmaceutical industry / Drug safety / Clinical research / Investigational New Drug / Treatment IND / Center for Drug Evaluation and Research / Drug development / Expanded access / New drug application

Microsoft Worddoc

DocID: 1qVAJ - View Document